الفهرس 
Phosphotidyl SerineOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
Portal vein thrombosis (PVT) is a well recognized complication of end stage liver diseases . It has been related to neoplasm ,liver dysfunction and hypercoaguable states. In recent years there has been growing interest and recognition of the antiphospholipid antibodies in association with acquired hypercoaguable states and considered one of the most common causes ofnon -tumor related portal vein thrombosis.
In the present study we aim to determine the level of antiphospholipid antibodies in patients with liver cirrhosis with and without portal vein thrombosis in a trial to find out any possible relation between these antibodies and the occurrence of PVT.
Our patients were divided into two groups; group A included 20 patients with liver cirrhosis without portal vein thrombosis and group B included 10 patients with hvcr cirrhosis and portal vein thrombosis.
All patients in this study were submitted to a full history taking,
throughout clinical examination, abdominal ultrasonography,
complete blood count, serum creatinin, ESR and liver function tests (AST, ALT, serum bilirubin, total protein and prothrombin time) with screening of viral hepatitis (HCV and HBV infection). Special investigation include assay of lupus anticoagulant and anticardiolipin antibodies (IgG and IgM).
Our results revealed a significant increase in levels of antiphospholipid antibodies (IgG) in patient with liver cirrhosis and portal vein thrombosis compared to patients with liver cirrhosis without portal vein thrombosis. While no significant difference was found between the two groups as regard to IgM. This was in parallel with the degree of liver injury as it was more pronounced in Child